Introduction
Combined oral contraceptive steroids (OCs) are prescribed for 17% of fertile women with epilepsy, which is almost as frequent as for the background population (25%). 1 Co-administration of OCs and antiepileptic drugs (AEDs) is therefore a common clinical situation which calls for specific considerations of possible drugs interactions. The main consequences of these interactions are risks of unintended pregnancy or seizure deterioration. A contraceptive failure may be disastrous for all women but is of specific clinical concern for women treated with AEDs because of the teratogenetic potential of the drugs. On the other end of the clinical spectrum may recurrence of even a single seizure in a seizurefree woman have detrimental psycho-social consequences.
A surprising number of physicians do not have adequate knowledge about potential interactions between their AEDs and the OCs 1 and approximately Summary The occurrence of bi-directional drug interactions between antiepileptic drugs (AEDs) and combined oral contraceptives (OCs) pose potential risks of unintended pregnancy and as well as seizure deterioration. It is well established that several of the older AEDs (carbamazepine, phenytoin and phenobarbital), are strong inducers of the hepatic cytochrome P450 (CYP) 3A4 enzyme system, and are associated with increased the risk of contraceptive failure. In addition, it is demonstrated that also some of the newer AEDs, oxcarbazepine and topiramate influence on the pharmacokinetics of OCs, which is thought to be due to a more selective induction of subgroups of the hepatic enzyme system.
Estrogens containing OCs induce the glucuronosyltransferase and may reduce the plasma levels and the effect of AEDs cleared by glucuronidation. This has been most intensively studied for lamotrigine but also other AEDs, which undergoes glucuronidation processes, such as valproate and oxcarbazepine, may be affected by OCs.
The magnitude of the drug-drug interactions show in general wide inter-individual variability and the change in the elimination rate is often unpredictable and can be influenced by a number of co-variants such as co-medication of other drugs, as well as genetic and environmental factors. It is therefore recommended that change in OC use is assisted by AED monitoring whenever possible. # 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
50% of women with epilepsy taking OC indicate that they have never been given information about this specific issue. 2 A recent survey, however, has shown that women with epilepsy of childbearing age do not always recall being given information on contraception and pre-pregnant planning, which highlights the need for regular repetitions. 3 The objective of this paper was to review the literature of the bi-directional interaction potentials between AEDs and OCs and to discuss the gaps of current knowledge in a future perspective.
The effect of AEDs on the pharmacokinetics of combined OCs
A drug interaction potential between AEDs and OCs was suggested for the first time in the beginning of the 1970s about 10 years after the introduction of the combined OC. A higher incidence of breakthrough bleeding and contraceptive failure among women with epilepsy was observed and correlated with the time when the ethinylestradiol fraction of OCs was decreased from 50-100 to <50 mg to diminish the risk of thrombo-embolic side effects. The contraceptive failure, therefore, was regarded as mainly dependent on the concentration of the estrogen fraction of the OC.
Modern available combined OC preparations contain 20-35 mg of ethinylestradiol and less than 1 mg of progestogen. The major part of the estrogen compound is hydroxylated to inactive metabolites by the hepatic cytochrome P450 (CYP) 3A4 or directly conjugated. AEDs that induce the CYP 3A4 isoenzyme (carbamazepine, 4 felbamate, 5 oxcarbazepine, 6 phenobarbital, 7 phenytoin 4 and topiramate) 8 may therefore accelerate the hepatic elimination of OCs. A recent study of topiramate with an OC containing 35 mg ethinyl estradiol demonstrated that topiramate monotherapy in dose <200 mg did not significantly affect the clinical efficacy of OCs. 9 The consequences of the drug interaction are a risk of contraceptive failure and un-intended pregnancy. Women who are prescribed drugs with a enzyme inducing potential, have therefore been advised to use high-dose OCs with a dose of the estrogen compound of at least 50 mg (low-dose topiramate monotherapy 35 mg) and should be advised to use additional barrier methods of contraception, especially in case of intramenstrual bleeding.
The extent of enzyme induction is correlated to the dose of the drug but is difficult to quantify as also genetic and environmental factors influence the hepatic isoenzyme expression. 10 Data available today suggest that neither of the other newer AEDs; gabapentin, 11 levetiracetam, 12 tiagabine, 13 vigabatrin 14 or zonisamide 15 influence the metabolism of OC and can be administrated without risk of contraceptive failure. One study has demonstrated a modest and probably not clinical relevant decrease of the levonorgestrel compound of the OCs during lamotrigine but no change in the pharmacokinetic parameters of ethinylestradiol. 16 This is in agreement with the former study by Holdich et al. 17 who found no effect of lamotrigine on the elimination of OCs. Similarly, it has been demonstrated that felbamate caused a 42% decrease in gestogene AUC (0-24) but had no effect on the metabolism of ethinylestradiol.
5 These studies by Sidhu et al. 16 and Saano et al. 5 however
The effect of combined OCs on the pharmacokinetics of AEDs
OCs can increase the metabolism of glucuronidated drugs by induction of the uridine diphosphate glucuronosyltransferase system. This has been most intensively studied for lamotrigine which is hepatically metabolized primarily by glucuronic acid conjugation. Several studies have demonstrated that lamotrigine is significantly and substantially (>50%) increased by combined OCs 16, [19] [20] [21] and that this interaction is associated with increased seizure frequency in most of the cases. 22 The contraceptive-induced pharmacokinetic alteration shows a considerable inter-individual variability based on probably both genetic factors and co-administration with other AEDs. This can be exemplified by the results in a recent study that revealed that the OC induction of lamotrigine elimination was almost eliminated when co-administrated with valproate. 23 The change in lamotrigine metabolism has been attributed to the estrogen rather than the progestin component of the OC 19 and is most likely caused by increased drug glucuronidation. 21 The lack of estrogens affects the pharmacokinetic acutely and the plasma level of lamotrigine increase in a fairly rapid and linear manner already within the ''pill-free'' week. 16, 21, 24 The clinical consequences are not fully explored but because of the rapid and significant increase of the plasma levels the authors suggest that the up-titration of lamotrigine dose should not occur in the ''pill-free week'' in order to avoid potential titration related tolerability problems. In addition, standardization of blood sampling in relation to the OC cycles is advisable for lamotrigine therapeutic monitoring. Personal clinical experience shows that overdose symptoms, in particular dizziness, may occur in single patients during the pill-free week on high-dose lamotrigine (plasma concentrations >40 mmol/l) and that a dose reduction of about 25% in the OC free week can be successful.
Recent results suggest that also other AEDs, eliminated fully or partly by glucuronidation, may have a similar interaction with combined OCs. Based on a single case Herzog et al. (2005) reported that plasma concentrations of valproate fluctuated widely during the OCs cycle. 25 A subsequent paper demonstrated that the plasma clearance of total valproate increased with a mean of 21.5% during OC intake period and of 45.2% for the unbound valproate fraction. 26 The OC effect on valproate clearance varied markedly across the subjects and may be of significant clinical relevance in some patients. Also the pharmacologically active monohydroxy derivate of oxcarbazepine is mainly eliminated by glucuronidation. The clinical relevance of this potential effect of OC also needs to be further explored.
In most studies, OCs affection on AEDs elimination rate shows a great inter-individual variability. The variability is probably multifactorial and reflects differences in dosages of the AEDs, the fraction cleared by conjugation, functional polymorphisms of glucuronosyltransferases and OC doses and formulations. As the level of altered elimination induced by OCs is unpredictable for the individual patient, it is recommended that the plasma level of all glucuronidated AEDs is carefully monitored and doses adjusted before and after introduction or discontinuation of OCs.
Other contraceptives than OCs
Data on possible interactions between AEDs and progesterone-only pill's, -injections and -implants are very sparse.
One study demonstrated that the subdermal levonorgestrel implants have a high failure risk in women receiving phenytoin. 27 These contraceptives are therefore generally regarded as less reliable and should not be prescribed in women who are treated with enzyme-inducing drugs.
The effect of intramuscular injection of 150 mg medroxyprogesterone acetate seems to be unaffected by enzyme inducing AEDs but the evidence is very limited. 28 Intrauterine contraceptives may be an optimal contraceptive choice for women treated with enzyme inducing AEDs. The levonorgestrel-releasing system delivers a local amount of hormone locally in the uterus and systemic drug interaction potential is low. However, one small study demonstrated that the contraceptive failure of this intrauterine device in 1.1% of women treated with AEDs compared to 0.2% in controls. 29 Copper intrauterine devices have a local spermicidal effect which is not regarded to be affected by concomitant drugs.
Perspectives
Although the potential of drug interactions between OCs and AEDs have been recognized for many years, there are still major gaps in the current knowledge and further explorations are needed. First of all, high-dose estrogen OCs may increase the risk of thrombo-embolic diseases and well as breast cancer. The extent of enzyme induction may be correlated to the dose of the AEDs but it is difficult to quantify, as genetic and environmental factors also affect hepatic isoenzyme expression. Therefore, a quantification of the enzyme induction, based on individual AEDs, dosages, genotypes for relevant drug metabolizing enzymes and types of co-medication, should be explored to avoid unnecessary high estrogen exposure. However, concerning the safety of the OCs it has always been a mantra to focus on the estrogen compound, as discussed further in this issue it might be more relevant to ensure safe contraception by adequate doses of the progestin compounds. This also stresses the importance of further explorations of the contraceptive safety and possible interactions between AEDs and progesterone-only pills, injections and patches and implants. Data available today suggest that the newer generation of AEDs are less likely to interact with OCs, but the enzyme inducing potential of all the newer AEDs have not be fully explored. Similarly there is an ongoing need to study the effects of OCs the elimination of AEDs and/or their active metabolites. This should especially be relevant for drugs where the elimination involves glucuronidation processes but also other elimination pathways may affected.
Conclusion
Treating women with epilepsy of fertile age includes systematic, ongoing and accurate counseling on optimal choice of contraception. The widely available range of AEDs stresses the importance of being Pharmacokinetic interactions between contraceptives & AEDsfamiliar with the various properties of the drugs and to achieve a better understanding of the drug-drug interactions and inter-individual variations. In case of change in the use of OCs, drug monitoring is recommended whenever possible. In future perspective there is an urgent need for prospective and systematic studies of the interaction potential on the pharmacokinetics of the different OCs and all the newer AEDs. Charting pharmacogenetic factors may be a valuable tool to provide an individualized treatment strategy and refine the contraceptive therapeutic planning to ensure the best possible health for the women. Until then the intrauterine contraceptives might be the first line contraceptive method at least for women who receive enzyme inducing AEDs.
